{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:42Z","timestamp":1793638962788,"version":"4.5.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-103955RB-100"],"award-info":[{"award-number":["PID2019-103955RB-100"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.drudis.2022.02.012","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T10:33:00Z","timestamp":1645266780000},"page":"1954-1960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy of repurposed antiviral drugs: Lessons from COVID-19"],"prefix":"10.1016","volume":"27","author":[{"given":"Miguel Angel","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.02.012_b0005","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1021\/acs.jcim.0c00861","article-title":"What are the odds of finding a COVID-19 drug from a lab repurposing screen?","volume":"60","author":"Edwards","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2022.02.012_b0010","doi-asserted-by":"crossref","unstructured":"Huang R, ZHu H, Shinn P, Ngan D, Ye L, Thakur A, et al. The NCATS Pharmaceutical Collection: a 10-year update. Drug Discov Today 2019; 24: 2341\u20132349.","DOI":"10.1016\/j.drudis.2019.09.019"},{"key":"10.1016\/j.drudis.2022.02.012_b0015","doi-asserted-by":"crossref","unstructured":"Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med 2017 234 2017; 23: 405\u2013408.","DOI":"10.1038\/nm.4306"},{"key":"10.1016\/j.drudis.2022.02.012_b0020","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021579118","article-title":"Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection","volume":"118","author":"Jan","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2022.02.012_b0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024302118","article-title":"Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay","volume":"118","author":"Jang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2022.02.012_b0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.chembiol.2021.01.021","article-title":"Nuisance compounds in cellular assays","volume":"28","author":"Dahlin","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2022.02.012_b0035","doi-asserted-by":"crossref","first-page":"e00411","DOI":"10.1128\/AAC.00411-17","article-title":"The race to find antivirals for zika virus","volume":"61","author":"Saiz","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.012_b0040","doi-asserted-by":"crossref","unstructured":"Bixler SL, Duplantier AJ, Bavari S. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis 2017 93 2017; 9: 299\u2013317.","DOI":"10.1007\/s40506-017-0130-z"},{"key":"10.1016\/j.drudis.2022.02.012_b0045","doi-asserted-by":"crossref","first-page":"e00399","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.012_b0050","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.012_b0055","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2022.02.012_b0060","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1016\/j.drudis.2022.02.012_b0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.02.012_b0070","doi-asserted-by":"crossref","unstructured":"Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2021 193 2020; 19: 149\u2013150.","DOI":"10.1038\/d41573-020-00016-0"},{"key":"10.1016\/j.drudis.2022.02.012_b0075","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2022.02.012_b0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.012_b0085","doi-asserted-by":"crossref","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020 303 2020; 30: 269\u2013271.","DOI":"10.1038\/s41422-020-0282-0"},{"key":"10.1016\/j.drudis.2022.02.012_b0090","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.drudis.2022.02.012_b0095","doi-asserted-by":"crossref","first-page":"e01897-20","DOI":"10.1128\/AAC.01897-20","article-title":"A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19","volume":"64","author":"Doi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.012_b0100","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1021\/jm400201a","article-title":"Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients","volume":"57","author":"Cho","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.012_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir against COVID-19 and other viral diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.02.012_b0110","doi-asserted-by":"crossref","unstructured":"Siegel D, Hui HC, Doeffler E, CLarke MO, Chun K, Zhang L, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo2,1-ftriazin-4-amino adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 2017; 60: 1648\u20131661.","DOI":"10.1021\/acs.jmedchem.6b01594"},{"key":"10.1016\/j.drudis.2022.02.012_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.635371","article-title":"Lack of Effectiveness of repurposed drugs for COVID-19 treatment","volume":"12","author":"Martinez","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2022.02.012_b0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-21","article-title":"Why remdesivir failed: preclinical assumptions overestimate the clinical efficacy of remdesivir for COVID-19 and Ebola","volume":"65","author":"Yan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.012_b0125","doi-asserted-by":"crossref","first-page":"e01101","DOI":"10.1128\/AAC.01101-20","article-title":"Clinical trials of repurposed antivirals for SARS-CoV-2","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.012_b0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.012_b0135","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.02.012_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2022.02.012_b0145","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.drudis.2022.02.012_b0150","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.02.012_b0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.02.012_b0160","doi-asserted-by":"crossref","unstructured":"de Wit W, Feldmann F, Cronin J, Jordan R, Okumura A, homas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117: 6771\u20136776.","DOI":"10.1073\/pnas.1922083117"},{"key":"10.1016\/j.drudis.2022.02.012_b0165","doi-asserted-by":"crossref","unstructured":"Grein J, Ohomagari N, Shin D, Diaz G, Asperges E, A Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382: 2327\u20132336.","DOI":"10.1056\/NEJMc2015312"},{"key":"10.1016\/j.drudis.2022.02.012_b0170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2022.02.012_b0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.02.012_b0180","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.02.012_b0185","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment With lopinavir\/ritonavir or Interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.012_b0190","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.02.012_b0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.drudis.2022.02.012_b0200","first-page":"ofaa241","article-title":"Antiviral activity and safety of darunavir\/cobicistat for the treatment of COVID-19. Open Forum","volume":"7","author":"Chen","year":"2020","journal-title":"Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.012_b0205","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy."},{"key":"10.1016\/j.drudis.2022.02.012_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.drudis.2022.02.012_b0215","unstructured":"FDA. EUA Hydroxychloroquine sulfate Health Care Provider Fact Sheet, version date 4\/27\/2020. Bethesda; FDA: 2020."},{"key":"10.1016\/j.drudis.2022.02.012_b0220","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(21)00461-X","article-title":"Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"397","author":"Butler","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2022.02.012_b0225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.medj.2020.06.001","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19","volume":"1","author":"Magagnoli","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.drudis.2022.02.012_b0230","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.medj.2020.06.001","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19","volume":"1","author":"Magagnoli","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.drudis.2022.02.012_b0235","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.012_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.012_b0245","unstructured":"FDA. www.fda.gov\/consumers\/consumer-updates\/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19. [Accessed February 15, 2022]."},{"key":"10.1016\/j.drudis.2022.02.012_b0250","first-page":"CD015017","article-title":"Ivermectin for preventing and treating COVID-19","volume":"7","author":"Popp","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2022.02.012_b0255","article-title":"Ivermectin, what the science says","author":"Baker","year":"2021","journal-title":"Nature. Published online August 6"},{"key":"10.1016\/j.drudis.2022.02.012_b0260","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-2600(21)00139-9","article-title":"Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context","volume":"9","author":"Angriman","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2022.02.012_b0265","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384: 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"10.1016\/j.drudis.2022.02.012_b0270","doi-asserted-by":"crossref","unstructured":"BM omazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 2020; 324: 1307\u20131316.","DOI":"10.1001\/jama.2020.17021"},{"key":"10.1016\/j.drudis.2022.02.012_b0275","first-page":"493","article-title":"Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19","volume":"27","author":"Florescu","year":"2021","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.drudis.2022.02.012_b0280","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","author":"Tummino","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.02.012_b0285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/hsz-2019-0270","article-title":"Emerging mechanisms of drug-induced phospholipidosis","volume":"401","author":"Breiden","year":"2019","journal-title":"Biol Chem"},{"key":"10.1016\/j.drudis.2022.02.012_b0290","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1126\/science.abj9488","article-title":"No shortcuts to SARS-CoV-2 antivirals","volume":"373","author":"Edwards","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.02.012_b0295","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 Antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2022.02.012_b0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-981-16-0267-2_6","article-title":"Discovery and development of antiviral therapies for chronic hepatitis C virus infection","volume":"1322","author":"Martinez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2022.02.012_b0305","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.02.012_b0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/d41586-021-00958-4","article-title":"The race for antiviral drugs to beat COVID - and the next pandemic","volume":"592","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.012_b0315","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/jac\/dkr090","article-title":"Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life","volume":"66","author":"Kumar","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2022.02.012_b0320","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.012_b0325","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cmdc.202000597","article-title":"The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: validating chemical probes","volume":"15","author":"Quancard","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2022.02.012_b0330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the coronavirus: 2019-nCoV","volume":"12","author":"Gralinski","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2022.02.012_b0335","doi-asserted-by":"crossref","first-page":"e01819","DOI":"10.1128\/JVI.01819-20","article-title":"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL pro inhibitor PF-00835231 as a potential new treatment for COVID-19","volume":"95","author":"de Vries","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.02.012_b0340","unstructured":"Clinical Trials Register. Clinicaltrials.gov [Accessed February 15, 2022]."},{"key":"10.1016\/j.drudis.2022.02.012_b0345","doi-asserted-by":"crossref","unstructured":"Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. MedRxiv. 2021: 2021.06.17.21258639.","DOI":"10.1101\/2021.06.17.21258639"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:39Z","timestamp":1761224439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462200071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S135964462200071X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.012","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of repurposed antiviral drugs: Lessons from COVID-19","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}